Eckert & Ziegler Strahlen und Medizintechnik AG
XHAM:EUZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XHAM:EUZ
|
DE |
|
Danske Andelskassers Bank A/S
CSE:DAB
|
DK |
|
W
|
Wildcat Resources Ltd
ASX:WC8
|
AU |
|
Tourmaline Bio Inc
NASDAQ:TRML
|
US |
|
U
|
UWC Bhd
KLSE:UWC
|
MY |
|
C
|
CWT International Ltd
HKEX:521
|
HK |
|
S
|
Star Money PCL
SET:SM
|
TH |
|
A
|
Aboitiz Equity Ventures Inc
XPHS:AEV
|
PH |
Wall Street
Price Targets
EUZ Price Targets Summary
Eckert & Ziegler Strahlen und Medizintechnik AG
According to Wall Street analysts, the average 1-year price target for
EUZ
is 21.01 EUR
with a low forecast of 17.12 EUR and a high forecast of 24 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is EUZ's stock price target?
Price Target
21.01
EUR
According to Wall Street analysts, the average 1-year price target for
EUZ
is 21.01 EUR
with a low forecast of 17.12 EUR and a high forecast of 24 EUR.
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Revenue forecast?
Projected CAGR
8%
For the last 14 years the
compound annual growth rate for
Eckert & Ziegler Strahlen und Medizintechnik AG's revenue is
7%.
The projected
CAGR
for the next 3 years is
8%.
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Operating Income forecast?
Projected CAGR
9%
For the last 14 years the
compound annual growth rate for
Eckert & Ziegler Strahlen und Medizintechnik AG's operating income is
9%.
The projected
CAGR
for the next 3 years is
9%.
What is Eckert & Ziegler Strahlen und Medizintechnik AG's Net Income forecast?
Projected CAGR
9%
For the last 14 years the
compound annual growth rate for
Eckert & Ziegler Strahlen und Medizintechnik AG's net income is
12%.
The projected
CAGR
for the next 3 years is
9%.
